echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JTO: Study on the prognostic value of KRAS G12C mutation in non-small cell lung cancer (NSCLC): from the European Thoracic Tumor Group's Lung Cancer Database Project

    JTO: Study on the prognostic value of KRAS G12C mutation in non-small cell lung cancer (NSCLC): from the European Thoracic Tumor Group's Lung Cancer Database Project

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Driver gene mutations play an important role in non-small cell lung cancer ( NSCLC ).


    Driver gene mutations play an important role in non-small cell lung cancer ( NSCLC ).


    Research data showed that 2055 patients underwent KRAS genetic testing, of which 1014 were adenocarcinoma (49%).


    Research data showed that 2055 patients underwent KRAS genetic testing, of which 1014 were adenocarcinoma (49%).


    Among 2055 patients, KRAS mutation was found in 473 patients (23.


    The median follow-up time was 57.



    Comparison of each group of os

    Among adenocarcinoma patients, the median RFS of patients with Kr_G12C mutation was 46.


    Among adenocarcinoma patients, the median RFS of patients with Kr_G12C mutation was 46.



    Comparison of RFS in each group

    Among adenocarcinoma patients , the median time to relapse (TTR) of patients with Kr_G12C mutation was 66.


    Among adenocarcinoma patients , the median time to relapse (TTR) of patients with Kr_G12C mutation was 66.



    TTR comparison of each group

    In summary, this large study showed that patients with lung adenocarcinoma with KRAS G12C mutations have a poor prognosis.


    In summary, this large study showed that patients with lung adenocarcinoma with KRAS G12C mutations have a poor prognosis.


    Original source:

    Stephen P Finn, Alfredo Addeo, Urania Dafni, et al.


    Stephen P Finn, Alfredo Addeo, Urania Dafni, et al.
    Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
    J Thorac Oncol.
    2021 Jun;16(6):990-1002.
    doi: 10.
    1016/j.
    jtho.
    2021.
    02.
    016.
    Epub 2021 Feb 26.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.